Sydney University is helping an ASX-listed company take a serious look at Australia's medical cannabis market

Warning message

The subscription service is currently unavailable. Please try again later.

The medical cannabis industry is getting down to business as the Australian government and numerous states back plans to let seriously ill patients use marijuana as a treatment.

On 17 October, the Turnbull government revealed plans to legalise growing cannabis for medicinal and scientific purposes, while Victorian premier Daniel Andrewsalso announced last month that his state would legalise the drug for medical use in 2017, including children with severe epilepsy.

NSW premier Mike Baird is planning trials for next year, and a parliamentary committee is due to report shortly on how they will be conducted.

Meanwhile, European medical grade cannabis business MGC Pharmaceuticals, which listed on the ASX via a reverse takeover of Perth-based Erin Resources, has announced plans to collaborate with the University of Sydney’s business school on research and commercial opportunities for the drug.

The company is already working on cannabis-based cosmetics and is now positioning itself to...

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.